ZMI Pharma, Inc. is a California corporation founded by Richard Hertzberg, John Jellinek, and Sam Kabbani. The founders have significant backgrounds in the life sciences and addiction management businesses, and the management of research and development programs.


ZIMHI™ is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, including fentanyl poisoning, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI™ is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI™ offers the highest dose of naloxone available as an intramuscular injection (5 mg/0.5 mL naloxone hydrochloride solution), and is packaged in a single-dose, pre-filled syringe. It is available by prescription.
Our Facility
We are excited to be the new manufacturer of ZIMHI™, a medication critical to combating the opioid epidemic in this country. Its high concentration of naloxone and effective delivery system makes ZIMHI™ a crucial tool in the fight against the rising tide of fentanyl poisonings.





Slider-1
Slider-2
Slider-3
Slider-4
Slider-5
